StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Investment analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of BLPH opened at $0.04 on Friday. The firm has a 50 day simple moving average of $0.04 and a 200-day simple moving average of $0.05. Bellerophon Therapeutics has a 1-year low of $0.03 and a 1-year high of $0.10. The stock has a market cap of $452,510.00, a price-to-earnings ratio of -0.04 and a beta of 0.71.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.